Lipidomic Evidence for Cannabidiol-Induced Remodeling of Cellular Lipid Composition in SH-SY5Y Cells.

Walzer O.; Erhardt V.; Zügner J.; Izarova N.; Endres K.; Grimm H.; Hartmann T.; Grimm M. · Cells · 2026

**Background & Methods** This in vitro lipidomic study examined cannabidiol (CBD) effects on cellular lipid composition using SH-SY5Y neuroblastoma cells, comparing wildtype cells with those stably expressing amyloid precursor protein with the Swedish mutation (APPswe) relevant to Alzheimer's disease modeling. Targeted lipidomic analysis was employed to characterize changes in lipid classes and individual species. **Key Findings** • CBD induced broad, class-specific lipid remodeling including increased total diacyl and ether-linked phosphatidylcholines, with a shift toward lower degrees of unsaturation within these classes, while highly polyunsaturated ether-linked phosphatidylcholines declined. • Lysophosphatidylcholines were broadly reduced, total sphingomyelin abundance decreased, and free carnitine along with most acylcarnitine species declined, collectively indicating a shift toward a less polyunsaturated lipid profile in wildtype cells. • CBD-associated changes in both phosphatidylcholine classes were replicated in APPswe-expressing cells, suggesting these effects persist in a model more relevant to Alzheimer's disease pathology and linking CBD to AD-relevant lipid dysregulation patterns. **Dosage & Administration** Not reported. **Safety & Adverse Effects** Not reported. **Evidence Quality** This is an in vitro cell culture study with significant limitations for clinical translation. The research represents an early mechanistic investigation using a single neuronal cell line model, which does not recapitulate the complexity of intact nervous tissue or whole-organism physiology. While the inclusion of both wildtype and APPswe-expressing cells strengthens the AD-relevance, findings cannot be directly extrapolated to in vivo effects or human patients. The study is hypothesis-generating rather than definitive, providing rationale for functional studies in more complex models. No information on CBD concentrations tested, exposure duration, or biological replicates is provided in the abstract. As a 2026 publication in a peer-reviewed journal, the study undergoes editorial scrutiny, though cell-based lipidomic studies represent relatively low-level evidence compared to clinical trials.

More recent cannabis research